MediStem was founded in 2005 to develop, acquire and commercialize adult stem cell based therapeutic products. The company currently has 16 families of patent applications, Numerous scientific publications, and has out-licensed certain technologies to generate revenue. Medistem’s main candidate, the Endometrial Regenerative Cell is a universal donor pluripotent stem cell, currently being developed for an advanced form of peripheral artery disease called critical limb ischemia.
MediStem, Inc. is a biotechnology company developing and commercializing technologies related to adult stem cell extraction and manipulation for use in treating inflammatory and degenerative diseases. The company’s lead product, the endometrial regenerative cell (ERC), is a “universal donor” stem cell derived from menstrual blood. ERC’s possesses the ability to differentiate into nine tissue types, produce large quantities of growth factors, and can be easily administered without need for invasive procedures. Due to MediStem’s relationships and collaborative efforts with respected institutions, MediStem believes it is well positioned to be a leading developer of adult stem cell products.